Gender Differences in Angiotensin-Converting Enzyme (ACE) Activity and Inhibition by Enalaprilat in Healthy Volunteers
- 1 May 2004
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Cardiovascular Pharmacology
- Vol. 43 (5), 737-744
- https://doi.org/10.1097/00005344-200405000-00018
Abstract
This bioequivalence study was supported by Laboratorios Vita S.A (Barcelona). To study the existence of differences between sexes in the pharmacokinetic and pharmacodynamic of enalapril. A bioequivalence phase 1 clinical trial to compare two formulations of enalapril was carried out in twenty-four healthy volunteers (12 men and 12 women). Enalaprilat concentrations, plasma activity of ACE, and systolic and diastolic arterial pressure were determined. Basal activity of ACE and the maximum ACE inhibition were significantly smaller in women. No significant differences in the drug concentration required to produce 50% of Emax were observed. Women had lower systolic arterial pressures and ACE activities than men at any time, even when the maximum inhibition of the ACE activity was attained. Women at the follicular phase had a minimum activity of ACE significantly inferior than men. Healthy women had lower systolic arterial pressures and ACE activities than men.Keywords
This publication has 26 references indexed in Scilit:
- Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptorsJournal Of Hypertension, 1998
- EnalaprilDrugs, 1992
- Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjectsEuropean Journal of Clinical Pharmacology, 1991
- Kinetic-dynamic relations and individual responses to enalapril.Hypertension, 1990
- Short- and Long-Term Determinants of Cardiovascular Function and TherapyJournal of Cardiovascular Pharmacology, 1989
- Effect of Cimetidine on the Pharmacokinetics and Pharmacodynamics of Enalapril in Normal VolunteersJournal of Cardiovascular Pharmacology, 1988
- Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.British Journal of Clinical Pharmacology, 1986
- Pharmacokinetics of repeated single oral doses of enalapril maleate (mk‐421) in normal volunteersBiopharmaceutics & Drug Disposition, 1984
- Enalapril maleate and a lysine analogue (MK‐521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.British Journal of Clinical Pharmacology, 1982
- Enalapril maleate and a lysine analogue (MK-521): disposition in man.British Journal of Clinical Pharmacology, 1982